One study, multiple immunotherapy combinations for hormone-receptor-positive, HER2-negative breast cancer

April 23, 2018

Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute. The study will evaluate several immunotherapy-based combination treatments. In the first stage, patients will receive either standard chemotherapy (fulvestrant) or a combination of treatments including the immunotherapy Tecentriq (atezolizumab). Those whose disease progresses or who no longer benefit may be eligible to receive a new combination of treatments in stage 2 of the study. New treatment arms may be added on the basis of ongoing clinical efficacy and safety. Medical Oncologist Alison Conlin, M.D., leads the study for Providence.

Read more in Breast Cancer News.

See study details here:
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS)

24 breast cancer studies are currently open
This study is one of 24 ongoing research studies investigating a broad spectrum of breast cancer therapies and interventions at Providence Cancer Institute. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from small phase I clinical trials to larger international studies, including studies from the National Cancer Institute, our own NCI Community Oncology Research Program (the Pacific Cancer Research Consortium), and pharmaceutical industry partners. Our own investigator-initiated research studies, available exclusively at Providence Cancer Institute, focus on novel approaches that harness the immune system to treat cancer.

New research studies are added frequently. Please visit our website to see all breast cancer studies currently open at Providence Cancer Institute. For more information or to enroll a patient, call our Clinical Trials office at 503-215-2614.

A team of breast cancer specialists
The research team at the Earle A. Chiles Research Institute at Providence Cancer Institute includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.